Once daily vs twice daily aspirin in patients after a heart operatio

Phase 1

• Conditions: Patients having successfully undergone coronary artery bypass graft (CABG) surgery; Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]

• Registration Number: EUCTR2011-002233-19-SE
• Lead Sponsor: Karolinska Institute

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-09-07
• Study Completion: 2015-07-01
• Last Update Posted: 19 April 2022

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 42

Inclusion Criteria

- Stable CAD patients scheduled to undergo elective CABG surgery

- Willing to participate and able to provide informed consent

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 40
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 20

Exclusion Criteria

- Patients taking drugs other than aspirin that are known to influence platelet function, including nonsteroidal anti-inflammatory drugs (NSAIDs, including COX-2 selective anti-inflammatory drugs), GPIIbIIIa inhibitors, clopidogrel, dipyridamole, warfarin or acenocoumarol within 7 days of enrolment

- Hemorrhagic diathesis or known platelet dysfunction

- Patients with chronic renal failure requiring dialysis

- Patients with a platelet count outside the 100 000 to 450 000/µL range

- Patients with severe anaemia (Haemoglobin < 8g/dl)

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified